3 ‘Perfect Ten’ Healthcare Stocks That Analysts Rate as a Strong Buy
We are diving into three healthcare stocks which all have a Strong Buy consensus and a 10 out of 10 TipRanks Smart Score. The Smart Score is a prop...
Royalty Pharma Plc (RPRX)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Hosking Partners Jeremy Hosking | 488,108 | $27,368,216 | -2% | 0.91% |
| 2. | Horizon Asset Management Murray Stahl | 344,861 | $19,336,349 | +2% | 0.22% |
| 3. | Quantedge Capital Pte Ltd Leow Kah Shin And Chua Choong Tze | 45,500 | $2,551,185 | 1.93% | |
| 4. | Sciencast Management Qing Li | 30,073 | $1,686,193 | -32% | 0.35% |
| 5. | Winton Capital Management David Harding | 22,800 | $1,278,396 | 0.04% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $29.51 | 130,000 | $3,836,768.00 | 600,000 | 2023-06-28 | Filing | |
| $32.78 | 45,000 | $1,474,902.00 | 470,000 | 2023-06-13 | Filing | |
| $33.00 | 45,000 | $1,484,946.00 | 425,000 | 2023-06-12 | Filing | |
| $32.25 | 150,000 | $4,837,440.00 | 380,000 | 2023-05-24 | Filing | |
| $32.94 | 69,612 | $2,293,095.85 | 230,000 | 2023-05-17 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $55.88 | 9,099 | $508,453.94 | 0 | 2026-07-01 | Filing | |
| $57.09 | 600 | $34,254.00 | 40,000 | 2026-06-30 | Filing | |
| $56.44 | 29,400 | $1,659,403.62 | 40,600 | 2026-06-30 | Filing | |
| $57.10 | 2,554 | $145,841.32 | 459,399 | 2026-06-30 | Filing | |
| $56.50 | 97,446 | $5,505,971.85 | 461,953 | 2026-06-30 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 27,832,977 | $1,560,595,060 | 0.02% | |
| 2. | 12,338,229 | $691,804,500 | 0.02% | |
| 3. | 10,726,608 | $601,440,912 | 0.52% | |
| 4. | 10,015,578 | $561,573,459 | 0.51% | |
| 5. | 3,723,864 | $208,797,054 | 0.05% |
News See All
Royalty Pharma, plc (RPRX) Rallied on Earnings Beat
Meridian Funds, managed by ArrowMark Partners, released its first-quarter 2026 investor letter for “Meridian Hedged Equity Fund”. A copy of the letter can be downloaded here.
Royalty Pharma (RPRX) Benefits from Biotech Funding Gap with Rising Returns and Market Dominance
Latitude Investment Management, an investment management firm, released its fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Royalty Pharma plc (NASDAQ:RPRX) Q1 2026 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by. Welcome to the Royalty Pharma First Quarter 2026 Earnings Conference Call.
Why Royalty Pharma Plc (RPRX) is One of the Most Undervalued Biotech Stocks to Buy Right Now
Royalty Pharma Plc (NASDAQ:RPRX) is one of the most undervalued biotech stocks to buy right now. Royalty Pharma Plc (NASDAQ:RPRX) announced on April 17 that its board of directors approved the payment...
8 Most Undervalued Biotech Stocks to Buy Right Now
On April 13, Tom Lee, Fundstrat's head of research, appeared on CNBC’s 'Power Lunch' to talk about his outlook on equities, what to expect in a wartime economy, and more.
Royalty Pharma plc (RPRX) Proved Resilience in Q1 by Gaining 25.6%
Patient Capital Management, based in Baltimore, released its first-quarter 2026 investor letter for the “Patient Opportunity Equity Strategy,” available for download here.
Royalty Pharma plc (RPRX) Earns $51 Target as 2026 Growth Outlook Exceeds Expectations
On February 12, Goldman Sachs raised its price target on Royalty Pharma plc (NASDAQ:RPRX) to $51 from $45 and maintained a Buy rating after strong Q4 results.
Royalty Pharma (RPRX) Achieves Record Growth and Hits Investment Targets Ahead of Schedule
Royalty Pharma (NASDAQ:RPRX) is one of the dirt cheap stocks to buy now.
12 Dirt Cheap Stocks to Buy Now
On February 23, Pierre Ouimet, head investment strategist at UBS Canada, joined BNN Bloomberg to discuss the markets and provide a spotlight on undervalued sectors.